Open AccessComparing Medications for DSM-5 PTSD in Routine VA Practice
Author(s) -
Brian Shiner,
Christine E. Leonard,
Jiang Gui,
Sarah Cornelius,
Paula P. Schnurr,
Jessica E. Hoyt,
Yig YoungXu,
Bradley V. Watts
Publication year - 2020
Publication title -
the journal of clinical psychiatry/the journal of clinical psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 207
eISSN - 1534-8628
pISSN - 0160-6689
DOI - 10.4088/jcp.20m13244
Subject(s) - venlafaxine , sertraline , fluoxetine , paroxetine , topiramate , psychiatry , veterans affairs , medicine , depression (economics) , psychology , anxiety , antidepressant , receptor , macroeconomics , serotonin , economics , epilepsy
Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have previously shown efficacy for posttraumatic stress disorder (PTSD). One prior study using US Department of Veterans Affairs (VA) medical records data to compare these agents found no differences in symptom reduction in clinical practice. The current study addresses several weaknesses in that study, including limited standardization of treatment duration, inability to account for prior treatment receipt, use of an outdated symptomatic assessment for PTSD, and lack of functional outcome.